Impact of diabetes and glycated hemoglobin level on the clinical manifestations of Parkinson's disease

Diabetes, Glycated Hemoglobin ( HbA1c) , and Neuroaxonal Damage in Parkinson's Disease ( MARK‐PD Study )

(2022) Merve Uyar et al.   MOVEMENT DISORDERS

The Impact of Type 2 Diabetes in Parkinson's Disease

(2022) Dilan Athauda et al.   MOVEMENT DISORDERS

Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort

(2022) Alexander S. Mihaescu et al.   Molecular Brain

Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease

(2021) Ioanna Markaki et al.   MOVEMENT DISORDERS

Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression

(2021) Harneek Chohan et al.   MOVEMENT DISORDERS

Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein

(2021) Ivan Martinez-Valbuena et al.   Acta Neuropathologica Communications

Diabetes Mellitus and Parkinson’s Disease: A Systematic Review and Meta-Analyses

(2021) Klara Komici et al.   Journal of Parkinsons Disease

IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045

(2021) Hong Sun et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease

(2020) Julia L.Y. Cheong et al.   Journal of Parkinsons Disease

Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes

(2020) Ruth Brauer et al.   BRAIN

Update of the MDS research criteria for prodromal Parkinson's disease

(2019) Sebastian Heinzel et al.   MOVEMENT DISORDERS

Cardiovascular Disease, Diabetes Mellitus, and Hypertension in Lewy Body Disease: A Comparison with Other Dementia Disorders

(2019) Keivan Javanshiri et al.   JOURNAL OF ALZHEIMERS DISEASE

Diabetes mellitus and Parkinson disease

(2018) Gennaro Pagano et al.   NEUROLOGY

Combined use of dopamine transporter imaging (DAT-SPECT) and 123 I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson's disease

(2017) Fumihito Yoshii et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes

(2016) Hiroaki Fujita et al.   PLoS One

MDS clinical diagnostic criteria for Parkinson's disease

(2015) Ronald B. Postuma et al.   MOVEMENT DISORDERS

Reliability of the Japanese version of the scales for outcomes in Parkinson's disease-autonomic questionnaire

(2014) Masaaki Matsushima et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease

(2013) Laura Dunn et al.   NEUROBIOLOGY OF AGING

Nocturnal disturbances and restlessness in Parkinson's disease: Using the Japanese version of the Parkinson's disease sleep scale-2

(2012) Keisuke Suzuki et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Central Dopaminergic Activity Influences Metabolic Parameters in Healthy Men

(2012) Ludmila Brunerova et al.   NEUROENDOCRINOLOGY

Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia

(2012) S. N. Gomperts et al.   NEUROLOGY

Evaluation of a Japanese version of the Mini-Mental State Examination in elderly persons

(2011) Yuki Ideno et al.   Geriatrics & Gerontology International

Development of a Japanese version of the Epworth Sleepiness Scale (JESS) based on Item Response Theory

(2008) Misa Takegami et al.   SLEEP MEDICINE